Nanoparticle albumin-bound paclitaxel is superior to liposomal paclitaxel in the neoadjuvant treatment of breast cancer.

Abstract

Aim: The present study aimed to retrospectively compare the efficacy and safety between liposomal paclitaxel (Lps-P) and nanoparticle albumin-bound paclitaxel (Nab-P) in neoadjuvant systemic treatment (NST) of breast cancer. Materials & methods: Two hundred thirty-five patients who were diagnosed with invasive breast cancer and then received dose-dense NST with epirubicin and cyclophosphamide followed by paclitaxel were enrolled. Results: Nab-P has an advantage in improving the total and axillary-only pathologic complete response rate over Lps-P. Although Nab-P can cause a higher incidence and severity of peripheral sensory neuropathy (PSN), most symptoms are temporary and reversible. In the Lps-P group, the proportion of patients with residual irreversible PSN is larger. Conclusion: Nab-P might be superior to Lps-P in NST of breast cancer.

• Authors: Weiwei Zhang, Yinggang Xu, Xiaoqing Shi, Xiaofeng Huang, Rui Chen, Haiping Xu, Wenjie Shi, Xinyu Wan, Ye Wang, Jinzhi He, Cuiying Li, Jue Wang, Xiaoming Zha
• Journal: Nanomedicine (London, England) (Nanomedicine (Lond)) Vol. 17 Issue 10 Pg. 683-694 (04 2022) ISSN: 1748-6963 [Electronic] England
• PMID: 35393861 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Albumin-Bound Paclitaxel
• Albumins
• Lipopolysaccharides
• Paclitaxel

Topics

• Albumin-Bound Paclitaxel (therapeutic use)
• Albumins (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols
• Breast Neoplasms (drug therapy, pathology)
• Female
• Humans
• Lipopolysaccharides
• Nanoparticles
• Neoadjuvant Therapy
• Paclitaxel (therapeutic use)
• Retrospective Studies
• Treatment Outcome